New coverage decisions by private payers and Medicare for OAB and urge incontinence

Published on November 27, 2012 at 8:43 AM · No Comments

Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced significant new coverage decisions by private payers and Medicare. 

Effective October 2012, Health Net®, one of the largest private insurance payers in California, began covering posterior tibial nerve stimulation (PTNS) for the treatment of overactive bladder (OAB) and associated symptoms of urgency, frequency and urge incontinence.  Health Net plans cover approximately 2.5 million beneficiaries, primarily in California, as well as in Arizona and Oregon.    

Also as of October, Medica®, a Minnesota-based private payer added PTNS coverage for approximately 1.7 million beneficiaries in Minnesota, North Dakota, South Dakota and Wisconsin. Further, Health First of Florida acknowledged coverage of PTNS for approximately 120,000 regional beneficiaries.

Additionally, three Medicare administrators, Noridian® Administrative Services LLC and Palmetto GBA®  J1 and J11, have expanded PTNS coverage from 1 to 2 years based upon recently published data demonstrating sustained therapeutic effects from continued PTNS treatments. Noridian® Administrative Services LLC is the Medicare administrator for Arizona, Alaska, Idaho, Montana, North Dakota, South Dakota, Utah, Washington and Wyoming. Palmetto GBA®  J1 is the Medicare administrator for California, Nevada and Hawaii and Palmetto GBA® J11 is the Medicare administrator for North Carolina, South Carolina, Virginia and West Virginia.  This extension will ensure that Medicare beneficiaries with OAB who are currently being treated successfully with PTNS will be able to continue to receive this effective therapy.

Three-year PTNS data, presented in October 2012 at the Western Section of the American Urological Association in Waikoloa, HI, also demonstrated sustained therapeutic effects from continued PTNS treatments, and is expected  to be available for publication in the near future.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post